Patent Application
20080015219
The following are hypothetical examples of useful compounds:
A compound of the formula
or a pharmaceutically acceptable salt thereof, or a prodrug thereof;
wherein a dashed line represents the presence or absence of a bond;
A is —(CH2)6—, cis-CH2CH═CH—(CH2)3—, or —CH2C≡C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein one CH2 may be replaced by S or O;
A compound which is a carboxylic acid or a bioisostere thereof, said carboxylic acid having a structure
or a pharmaceutically acceptable salt thereof, or a prodrug thereof;
wherein a dashed line represents the presence or absence of a bond;
A is —(CH2)6—, cis-CH2CH═CH—(CH2)3—, or —CH2C≡C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein one CH2 may be replaced by S or O;
The compound according to claim 1 wherein Y is selected from CO2R2, CON(R2)2, CON(OR2)R2, CON(CH2CH2OH)2, CONH(CH2CH2OH), CH2OH, P(O)(OH)2, CONHSO2R2, SO2N(R2)2, SO2NHR2,
wherein R2 is independently H, C1-C6 alkyl, unsubstituted phenyl, or unsubstituted biphenyl.
The compound according to claim 1 or 3 of the formula
or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
The compound according to claim 1 or 3 having the formula
or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
The compound according to claim 1 or 3 having the formula
or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
The compound according to any one of claims 1 to 6 wherein A is (3-methylphenoxy)methyl.
The compound according to any one of claims 1 to 6 wherein A is (4-but-2-ynyloxy)methyl.
The compound according to any one of claims 1 to 6 wherein A is 2-(2-ethylthio)thiazol-4-yl.
The compound according to any one of claims 1 to 6 wherein A is 2-(3-propyl)thiazol-5-yl.
The compound according to any one of claims 1 to 6 wherein A is 3-(methoxymethyl)phenyl.
The compound according to any one of claims 1 to 6 wherein A is 3-(3-propyl)phenyl.
The compound according to any one of claims 1 to 6 wherein A is 3-methylphenethyl.
The compound according to any one of claims 1 to 6 wherein A is 4-(2-ethyl)phenyl.
The compound according to any one of claims 1 to 6 wherein A is 4-phenethyl.
The compound according to any one of claims 1 to 6 wherein A is 4-methoxybutyl.
The compound according to any one of claims 1 to 6 wherein A is 5-(methoxymethyl)furan-2-yl.
The compound according to any one of claims 1 to 6 wherein A is 5-(methoxymethyl)thiophen-2-yl.
The compound according to any one of claims 1 to 6 wherein A is 5-(3-propyl)furan-2-yl.
The compound according to any one of claims 1 to 6 wherein A is 5-(3-propyl)thiophen-2-yl.
The compound according to any one of claims 1 to 6 wherein A is 6-hexyl.
The compound according to any one of claims 1 to 6 wherein A is (Z)-6-hex-4-phenyl.
The compound according to any one of claims 1, 3, and 6 to 22 having the formula
or a pharmaceutically acceptable salt thereof or a prodrug thereof.
The compound according to any one of claims 1, 3, and 6 to 22 having the formula
or a pharmaceutically acceptable salt thereof or a prodrug thereof.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is O.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is S.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is F.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is Cl.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is Br.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is 1.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is CN.
The compound according to any one of claims 1 to 3, and 7 to 22 wherein U1 is O-alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is hydrogen.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is F.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is Cl.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is Br.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is I.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is O.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is OH.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is CN.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is O-alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 32, wherein J1 is CF3.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 43 wherein J2 is O.
The compound according to any one of claims 1 to 3, 7 to 22, and 25 to 43 wherein J2 is OH.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted phenyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted thienyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted naphthyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted furyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted pyridinyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted benzothienyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted indanyl.
The compound according to any one of claims 1 to 45 wherein B is substituted or unsubstituted tetralonyl.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, 3, 4, or 5 substituents, wherein each substituent has one or more carbon, fluorine, chlorine, bromine, or oxygen atoms; and wherein all substituents taken together consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms; 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms; 0, 1, 2 or 3 chlorine atoms, 0, 1, 2 or 3 bromine atoms, and 0, 1, 2 or 3 oxygen atoms.
The compound according to any one of claims 1 to 45 wherein B has a substituent of the formula CaHbOc; wherein a is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19; and c is 0, 1, 2, or 3.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, 3, or 4 alkyl substituents having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
The compound according to any one of claims 1 to 45 wherein B has a hydroxyalkyl substituent having 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms and 1 or 2 hydroxy moieties.
The compound according to any one of claims 1 to 45 wherein B has an alkyl substituent having 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, 3, or 4 halogen substituents.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, 3, or 4 chloro substituents.
The compound according to any one of claims 1 to 45 wherein B has 1 chloro substituent.
The compound according to any one of claims 1 to 45 wherein B has 2 chloro substituents.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, 3, or 4 trifluoromethyl substituents.
The compound according to any one of claims 1 to 45 wherein B has 1, 2, or 3 trifluoromethyl substituents.
The compound according to any one of claims 1 to 45 wherein B has 1 trifluoromethyl substituent.
The compound according to any one of claims 1 to 45 wherein B has 2 trifluoromethyl substituents.
The compound according to any one of claims 1 to 45 wherein B has a hydroxyl substituent.
The compound according to any one of claims 1 to 46 wherein B is unsubstituted phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3,5-dichlorophenyl.
The compound according to any one of claims 1 to 46 wherein B is 3,5-di(trifluoromethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 2-chlorophenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-chlorophenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-chlorophenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(trifluoromethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-isopropylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-tert-butylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-hydroxyphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-methoxyphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(benzoyloxy)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 2,3-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3,4-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 2,4-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 2,5-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3,5-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 2,6-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(hydroxymethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(1-hydroxyethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(1-hydroxy-2-methylpropyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 2-(hydroxymethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(hydroxymethyl)-3,5-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(methoxymethyl)-3,5-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(1-hydroxybutyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(1-methoxybutyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(1-hydroxybutyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(2-hydroxyethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(2-hydroxyethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 2-(2-hydroxyethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(2-hydroxyethyl)-3,5-dimethylphenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(1-hydroxyhexyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 3-(acetoxymethyl)-5-chlorophenyl.
The compound according to any one of claims 1 to 46 wherein B is 1-oxo-2,3-dihydro-1H-inden-4-yl.
The compound according to any one of claims 1 to 46 wherein B is 1-hydroxy-2,3-dihydro-1H-inden-4-yl.
The compound according to any one of claims 1 to 46 wherein B is 5-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl.
The compound according to any one of claims 1 to 46 wherein B is 3-(1-hydroxy-2-phenylethyl)phenyl.
The compound according to any one of claims 1 to 46 wherein B is 4-(2-phenylpropan-2-yl)phenyl.
The compound according to any one of claims 1 to 45 wherein B is naphthalen-2-yl.
The compound according to any one of claims 1 to 45 wherein B is naphthalen-1-yl.
The compound according to any one of claims 1 to 45 wherein B is 4-chloronaphthalen-1-yl.
The compound according to any one of claims 1 to 22, and 25 to 108 wherein U1 is hydrogen.
The compound according to any one of claims 1 to 22, and 25 to 108 wherein U1 is OH.
The compound according to compound example 1 or 2 wherein said compound is not
The compound of claim 1 wherein B is not substituted or unsubstituted phenyl.
The compound of claim 1 or 112 wherein A is not (CH2)6.
The compound of claim 1 wherein if:
then B is not substituted or unsubstituted phenyl.
A composition comprising a compound according to any one of compound examples 1 to 114, wherein said composition is a liquid which is ophthalmically acceptable.
Use of a compound according to any one of compound examples 1 to 114 in the manufacture of a medicament for the treatment of glaucoma or ocular hypertension in a mammal.
Use of a compound according to any one of compound examples 1 to 114 in the manufacture of a medicament for the treatment of baldness in a person.
A medicament comprising a compound according to any one of compound examples 1 to 114, wherein said composition is a liquid which is ophthalmically acceptable.
A method comprising administering a compound according to any one of compound examples 1 to 114 to a mammal for the treatment of glaucoma or ocular hypertension.
A kit comprising a composition comprising compound according to any one of compound examples 1 to 114, a container, and instructions for administration of said composition to a mammal for the treatment of glaucoma or ocular hypertension.
“Treatment,” “treat,” or any other form of these words as used herein are intended to mean use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals.
Synthetic procedures described in U.S. Provisional Patent Application No. 60806813, filed on Jul. 10, 2006, may be adapted for use herein. For example, compound I in said reference may be substituted with compounds such as those shown below.
The α-chain A may be modified may be varied by following or adapting procedures found in U.S. Provisional Patent Application No. 60/805,285, filed on Jul. 20, 2006, which is expressly incorporated by reference herein, wherein an analog of the Corey lactone is used as the precursor to a Wittig reaction to install all the atoms of the α-chain; other Wittig reactions and the preparation of the requisite phosphonates are described by Collect. Czech. Chem. Commun. 1994, 58, 138-148, and Collect. Czech. Chem. Commun. 1994, 59, 2533-2544. Alternatively, the intermediate Corey lactone analog may be reduced to the corresponding primary alcohol, which may then be manipulated by methods known in the art to compounds bearing a heteroatom at the 5th (by alkylation of the alcohol or the derived thiol), 4th (by lengthening the chain by one atom (e.g. by homologation via the corresponding aldehyde)) or 6th (by shortening the chain by one atom (e.g. by ozonolysis of an enol ether derived from the corresponding aldehyde)) atom from the acid terminus.
Different J1, J2, and U1 substituents may be obtained by following or adapting procedures found in the following documents, all of which are expressly incorporated by reference herein:
Different substituted or unsubstituted aryl groups for B may be obtained by methods well known in the art. These analogs may be prepared by the reaction of an aldehyde obtained from the alcohols shown above with the anion of an aryl or heteroaryl methyl phosphonate, the latter being derived from the reaction of triphenylphosphine with the appropriate aryl or heteroaryl methyl halide (e.g., see Maryanoff, B. E., and Reitz, A. B., Chem. Rev. 1989, 89, 863-927 and references therein). The requisite aryl or heteraryl methyl halide, if not commercially available may be prepared from commercially available aryl or heteroaryl methyl alcohols (by halogenation), aryl or heteroaryl halides (by one carbon homogation via the aryl or heteroaryl methyl alcohol), or aryl or heteroaryl carboxylate compounds (by reduction and halogenation). Different substituted or unsubstituted aryl groups for B may also be obtained by the obtaining an analog for compound 3 using the procedures described in U.S. Pat. No. 6,531,485, expressly incorporated herein by reference, (see, e.g. compound 1-4, Scheme 3, columns 23-24), and varying J1, J2, and U1 as described above. Alternatively, conjugate addition reactions, analogous to reactions in U.S. Pat. No. 6,531,485, of styryl halides could be used to introduce different substituted aryl or heteroaryl groups for B. The requisite styryl halides may be prepared from the corresponding alkyne (via hydrohalogenation) or other organometallic methods known in the art.
The compounds disclosed herein are believed to be selective prostaglandin EP2 agonists, and are thus useful for the treatment of glaucoma, ocular hypertension, and other diseases or conditions.
The following are hypothetical examples demonstrating how a person may be treated with the compounds disclosed herein.
An aqueous liquid containing 0.1% of H1 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H2 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H3 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H4 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H5 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H6 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H7 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H8 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H9 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H10 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H 11 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H12 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H13 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H14 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H15 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H16 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H17 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H18 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H19 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H2O is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H21 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H22 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H23 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H24 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H25 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H26 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H27 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H28 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H29 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H30 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H31 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H32 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H33 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H34 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H35 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H36 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H37 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H38 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H39 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H40 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H41 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H42 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H43 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H44 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H45 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H46 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H47 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H48 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H49 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H50 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H51 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H52 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H53 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H54 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H55 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H56 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H57 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H58 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H59 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H60 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H61 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H62 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H63 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
An aqueous liquid containing 0.1% of H64 is given topically to the eye of a person suffering from elevated intraocular pressure. A few hours after administration, the person's intraocular pressure is reduced. The drop is administered twice a day, and pressure remains low for as long as the treatment is continued.
The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the claims.
This application is based, and claims priority under 35 U.S.C. § 120 to U.S. Provisional Patent Application No. 60/806,946, filed Jul. 11, 2006, and U.S. Provisional Patent Application No. 60/806,972 filed Jul. 11, 2006, and each of which is hereby incorporated by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60806946 | Jul 2006 | US | |
| 60806972 | Jul 2006 | US |
